Wolverine stack vs KLOW: differences, evidence and safety

Verdict: The Wolverine stack is BPC-157 plus TB-500; KLOW is the same pair plus GHK-Cu and KPV. Neither blend is FDA approved, both contain WADA-prohibited peptides, and no human trial has tested either mix. KLOW’s extra ingredients add topical human data (GHK-Cu) and mouse data (KPV), not evidence for the blend.

None of the four ingredients is an approved drug in the US, and all four appear on the FDA’s list of compounding nominations that were withdrawn from Category 2, which is not an approval. The WADA 2026 Prohibited List names BPC-157 (S0) and TB-500 (S2.3), so both blends are prohibited in sport at all times. The strongest evidence for the Wolverine pair is animal data plus one uncontrolled human chart review; the strongest evidence for anything in KLOW is small topical GHK-Cu trials that did not use the blend.

Item	Wolverine stack	KLOW
US FDA status	Not approved (FDA)	Not approved (FDA)
Compounding (503A/503B)	Both parts withdrawn from Category 2; neither on the 503A bulks list. The Pharmacy Compounding Advisory Committee voted 8–6 on 2026-07-23 to recommend both BPC-157 and TB-500 for 503A listing; advisory only, no FDA rule yet (FDA PCAC meeting)	All four withdrawn from Category 2; none on the 503A bulks list. The same committee voted 8–6 that day to recommend BPC-157, TB-500 and KPV for 503A listing; advisory only, no FDA rule yet. GHK-Cu was not voted on; FDA plans to consult the committee on it before the end of February 2027
WADA 2026	Prohibited: BPC-157 S0, TB-500 S2.3 (WADA)	Prohibited (same two); GHK-Cu and KPV not named
Strongest evidence	Human, uncontrolled (n=16, BPC-157)	Human RCT, topical GHK-Cu only
Human trials of the blend	0 (ingredient trials: BPC-157, 3 registered, none with posted results: NCT02637284, NCT07752381, NCT07803250; none of the TB-500 fragment)	0 (adds GHK-Cu: NCT07706361, not yet recruiting)
Last checked	2026-10-18	2026-09-30

Wolverine stack vs KLOW at a glance

Feature	Wolverine stack	KLOW
What it is	Two-peptide combination	Four-peptide premixed blend
Ingredients	BPC-157, TB-500	BPC-157, TB-500, GHK-Cu, KPV
Class	Unapproved synthetic peptides	Same, plus a copper peptide and an α-MSH fragment
Proposed mechanisms	Blood-vessel signaling via VEGFR2 (BPC-157, rat and lab); thymosin beta-4 active region (TB-500)	Adds collagen-related effects (GHK-Cu, lab) and NF-κB inhibition (KPV, lab)
Main research focus	Tendon, muscle and blood-flow models in rats	Adds skin wounds (GHK-Cu) and colitis models (KPV)
Human evidence, blend	None	None
Best human evidence, any part	Uncontrolled chart review, n=16 (Lee 2021)	Topical GHK-Cu RCT, diabetic ulcers (Mulder 1994)
Registered ingredient trials	BPC-157: 3 (NCT07803250, NCT02637284, NCT07752381); TB-500 fragment: 0 (the 19 registered thymosin beta-4 trials use the full-length protein)	Same, plus GHK-Cu: 1, not yet recruiting (NCT07706361); KPV: 0
FDA approval	None	None
Compounding	Withdrawn from Category 2	Withdrawn from Category 2
WADA 2026	Prohibited (S0, S2.3)	Prohibited (S0, S2.3)
Routes studied	Rats: several routes; humans: into the knee and IV (BPC-157, uncontrolled)	Adds topical skin (GHK-Cu, human) and oral in mice (KPV)
Timelines in studies	4 weeks (rat tendon)	No study of the blend
Main safety concerns	Immunogenicity (FDA), tumor-vessel signal for thymosin beta-4 in mice, unregulated manufacturing	Same, plus injectable GHK-Cu aggregation and no human exposure data for KPV (FDA)

What is the Wolverine stack?

“Wolverine stack” is a marketing name, not a product any regulator recognizes, for BPC-157 and TB-500 used together. BPC-157 is a synthetic 15-amino-acid peptide; a 2025 systematic review of its orthopedic research found 36 studies, of which 35 were preclinical and 1 was clinical. TB-500 is an acetylated seven-amino-acid fragment (LKKTETQ) of thymosin beta-4, identified in doping-control work as a synthetic version of that protein’s active region. Our BPC-157 vs TB-500 comparison sets the two ingredients against each other; this page covers what changes when two more are added.

What is KLOW?

KLOW is a premixed blend sold online that contains the two Wolverine peptides plus GHK-Cu and KPV. The ratio is set by each seller; no regulator or published study defines a standard formula. GHK-Cu is a copper-bound tripeptide (glycyl-histidyl-lysine) whose reported lab and animal actions include increased collagen and elastin. KPV (lysine-proline-valine) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), studied for anti-inflammatory effects. For how KLOW differs from GLOW, the three-peptide version without KPV, see KLOW vs GLOW vs GHK-Cu.

How do they work differently?

The shared pair is proposed to work the same way in both blends. The difference is what KLOW’s extra two ingredients are proposed to add:

• Wolverine (BPC-157): in rats with blocked leg arteries and in human vessel cells, BPC-157 increased VEGFR2 expression and sped blood-flow recovery [Animal; Lab].
• Wolverine (TB-500): its parent protein, thymosin beta-4, increased blood-vessel formation in mouse tumors, with a mean 4.4-fold rise in vessels [Animal]. No study identified here measures how much of that activity the TB-500 fragment keeps.
• KLOW adds GHK-Cu: a 2018 review summarizes lab and animal findings on collagen, elastin, and blood-vessel and nerve outgrowth [Lab; Animal].
• KLOW adds KPV: nanomolar KPV inhibited NF-κB and MAP kinase inflammatory signaling in intestinal cells [Lab]. KPV lacks the sequence needed to bind known melanocortin receptors, so it is not expected to act like melanotan-type peptides [review of Lab and Animal data].

So the Wolverine pair targets repair and blood supply, while KLOW layers a skin-matrix peptide and a gut-inflammation peptide on top. Each of those rationales comes from separate lab or animal studies; none comes from a study of the blend.

Evidence head-to-head

Each cell gives the strongest evidence level found and the study behind it. Where KLOW’s cell says “same,” the only relevant data come from the two peptides it shares with the Wolverine stack.

Outcome	Wolverine best evidence	KLOW best evidence
Tendon healing	Animal (rat, n=32): pair no better than either alone (Biçer 2026)	Same; no study adds GHK-Cu or KPV
Knee pain	Human, uncontrolled (n=16): 14 reported relief (Lee 2021)	Same; no data for added parts
Chronic skin ulcers	No TB-500 or BPC-157 human trial identified	Human RCT, topical GHK-Cu: 98.5% vs 60.8% median closure (Mulder 1994)
Skin after laser	None	Human RCT (n=13), topical GHK-Cu: higher satisfaction (Miller 2006)
Gut inflammation	No human trial	Animal (mice, oral KPV): less colitis (Dalmasso 2008)
Dry eye	Human RCT (n=72), full-length thymosin beta-4 eye drops, not TB-500 (Sosne 2015)	Same
Human safety	Pilot (n=2), IV BPC-157 (Lee 2025); RCT (n=40), IV full-length thymosin beta-4 (Ruff 2010)	Same; KPV has no human exposure data (FDA)
The blend itself	None	None

Three points stand out. First, KLOW’s extra human evidence is all topical GHK-Cu on skin; nothing shows that GHK-Cu mixed with other peptides and given another way behaves the same. Second, the knee chart review had no control group, and some of its patients also received thymosin beta-4, so it cannot separate either peptide’s effect [Human, uncontrolled, n=16]. Third, the one direct test of “more peptides is better” identified here went against the idea: in the rat tendon study, TB-500 alone showed a significant biomechanical advantage at four weeks, while the pair added nothing over single treatment [Animal, n=32].

Which fits which goal?

These are statements about where the evidence sits, not advice to use either product:

• The Wolverine pair has more evidence for tendon and muscle repair models, almost all in rats. The 2025 systematic review found one clinical study among 36 [review; mostly Animal].
• KLOW’s added ingredients have more evidence for skin outcomes, but only as topical GHK-Cu in small human trials; in one, on post-laser skin (n=13), patient-rated skin quality improved but blinded measures of redness, wrinkles and skin quality did not [Human RCT].
• KLOW’s KPV has evidence for gut inflammation only in rodents, including mice given oral KPV and rats given a KPV hydrogel for chemically induced colitis [Animal].
• Neither has evidence as a blend for any outcome in people.

For an injury, a skin condition or a gut disease, a clinician is the person to decide what is appropriate.

Can they be combined?

KLOW already contains the whole Wolverine stack, so using both would double the shared pair; no study has examined that. On the underlying question, whether combining these peptides adds anything, the evidence is thin and not encouraging: the one controlled comparison identified of BPC-157 plus TB-500 against each alone, in rats (n=32), found no added benefit [Animal]. No published study identified here has tested BPC-157, TB-500, GHK-Cu and KPV together. No controlled human study has tested either combination, and ClinicalTrials.gov listed no registered trial of either blend on 2026-09-30. A 2026 review of unregulated peptide use names “stacking” among the practices spreading outside clinical oversight.

Safety and regulatory status

Every risk that applies to the Wolverine stack applies to KLOW, which then adds two ingredients with their own open questions. The sources for each row are in the paragraphs below.

Issue	Wolverine stack	KLOW
FDA safety note	Possible immunogenicity for BPC-157 and TB-500	Same, plus aggregation risk for injectable GHK-Cu; no human exposure data for KPV
FDA advisory review (non-binding)	BPC-157 (ulcerative colitis) and TB-500 (wound healing) reviewed July 2026	KPV also reviewed; GHK-Cu not
WADA 2026	BPC-157 S0; TB-500 S2.3; prohibited at all times	Same; GHK-Cu and KPV not named
Theoretical cancer concern	Thymosin beta-4 linked to metastasis in mice	Same
Product quality	Unregulated manufacturing	Same, with four ingredients instead of two

United States. None of the four peptides is FDA approved. The FDA’s Category 2 page (updated 2026-04-22) lists all four as nominations that were withdrawn. It notes that compounded BPC-157 and TB-500 “may pose risk for immunogenicity,” that injectable GHK-Cu may pose that risk “due to the potential for aggregation,” and that the agency “has not identified any human exposure data” for KPV. Withdrawal from Category 2 does not place a substance on the 503A bulks list, and none of the four appears there. The Pharmacy Compounding Advisory Committee reviewed BPC-157 (for ulcerative colitis), KPV (for wound healing and inflammatory conditions) and TB-500 (for wound healing) on 2026-07-23; it makes non-binding recommendations to the FDA.

Sport. The WADA 2026 List names BPC-157 under S0 (non-approved substances) and “thymosin-β4 and its derivatives, e.g. TB-500” under S2.3 (growth factors). USADA confirms BPC-157 is prohibited under S0. Because both blends contain both peptides, both are prohibited at all times. GHK-Cu and KPV are not named on the List; S0 covers any pharmacological substance without government approval for human therapeutic use that no other section addresses, so their status on their own is a question for an anti-doping agency.

Known and theoretical risks. Melanoma cells engineered to overproduce thymosin beta-4 formed 46.7 versus 10.9 lung metastases in mice [Animal]; whether the TB-500 fragment carries this risk is untested. The 2025 orthopedic review warns that adverse effects are possible due to unregulated manufacturing, and a 2025 narrative review concludes BPC-157 “should be considered investigational.” A 2026 review of injectable “biohacking” drugs urges clinicians to counsel patients on long-term hazards. A four-ingredient blend also makes it harder to tell which component caused a reaction.

How long do effects take in studies?

No study reports a timeline for either blend. For the ingredients, the time points below are those the studies chose, not expected results in people:

• Rat Achilles tendon (BPC-157, TB-500, both): assessed after four weeks of postoperative treatment [Animal].
• Full-length thymosin beta-4 eye drops: discomfort in a controlled-environment test was 27% lower than placebo on day 28 [Human RCT, n=72].